Recent Updates — QNTM
The United States District Court for the Southern District of New York has agreed to consolidate Quantum BioPharma’s direct action and a class action alleging illegal stock market manipulation by Canadian banks CIBC and RBC. The court appointed Grant & Eisenhofer P.A. as lead counsel in the consolidated class action. The lawsuits allege that defendants used spoofing techniques between 2020 and 2025 to manipulate Quantum BioPharma's share price, causing material harm to shareholders who sold securities during that period. This ruling represents a procedural development in the ongoing litigation but does not constitute a determination on the merits of the claims or any finding of liability or damages. Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for neurodegenerative, metabolic, and alcohol misuse disorders.
Quantum BioPharma has entered into a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial for Lucid-MS, an investigational neuroprotective therapy for progressive multiple sclerosis. The execution of this contract marks the initiation of formal study start-up activities following FDA clearance to proceed with the randomized, double-blind, placebo-controlled study. Thermo Fisher will support the company in implementing the trial, including site activation and related clinical research services. Quantum BioPharma is a biopharmaceutical company focused on developing innovative therapies for neurodegenerative disorders.
Quantum Biopharma Ltd. filed a Form 6-K furnishing press releases from March 2025 to August 2026. Key events include the closing of debt settlements via share issuances, revisions to convertible debenture terms, and a private placement announcement. The filing also reports audited year-end financial results for December 31, 2025, noting $11.3 million in cash and digital assets, reduced operating expenses, and a 'No Going Concern' status with runway through January 2028. Additionally, it discloses the resignation of board member Terry Lynch and the completion of a special dividend distribution consisting of contingent value rights on October 27, 2025. Quantum Biopharma Ltd. is a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders.